Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes

PLoS Pathogens

Volumn 6, Issue 4, 2010, Pages 1-13

  Sionov, Edward ^a   Lee, Hyeseung ^a   Chang, Yun C ^a   Kwon Chung, Kyung J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; FUNGAL PROTEIN; PROTEIN AFR1; PROTEIN ERG11; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; PYRROLE DERIVATIVE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CHROMOSOME ANALYSIS; CHROMOSOME DUPLICATION; CONCENTRATION RESPONSE; CRYPTOCOCCUS NEOFORMANS; DISOMY; DRUG TOLERABILITY; EVOLUTIONARY ADAPTATION; FUNGAL STRAIN; GENE DOSAGE; GENE TARGETING; GENOMIC IN SITU HYBRIDIZATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SEROTYPE; CELL SEPARATION; CHROMOSOME; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; IN SITU HYBRIDIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

FILOBASIDIELLA NEOFORMANS;

ANTIFUNGAL AGENTS; AZOLES; CELL SEPARATION; CHROMOSOMES, FUNGAL; COMPARATIVE GENOMIC HYBRIDIZATION; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, FUNGAL; FLOW CYTOMETRY; FLUCONAZOLE; IN SITU HYBRIDIZATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77954047286     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000848     Document Type: Article

References (53)

1. Kwon-Chung KJ, Bennett JE (1992) Medical Mycology. Philadelphia: Lea & Febiger. 866 p.
2. Perfect JR, Casadevall A (2002) Cryptococcosis. Infect Dis Clin North Am 16: 837-874.
3. Zonios DI, Bennett JE (2008) Update on azole antifungals. Semin Respir Crit Care Med 29: 198-210.
4. Perfect JR, Cox GM (1999) Drug resistance in Cryptococcus neoformans. Drug Resist Updat 2: 259-269.
5. Kontoyiannis DP, Sagar N, Hirschi KD (1999) Overexpression of Erg11p by the regulatable GAL1 promoter confers fluconazole resistance in Saccharomyces cerevisiae. Antimicrob Agents Chemother 43: 2798-2800.
6. Lamping E, Monk BC, Niimi K, Holmes AR, Tsao S, et al. (2007) Characterization of three classes of membrane proteins involved in fungal azole resistance by functional hyperexpression in Saccharomyces cerevisiae. Eukaryot Cell 6: 1150-1165.
7. Akins RA (2005) An update on antifungal targets and mechanisms of resistance in Candida albicans. Med Mycol 43: 285-318.
8. Bennett JE, Izumikawa K, Marr KA (2004) Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother 48: 1773-1777.
9. Brun S, Berges T, Poupard P, Vauzelle-Moreau C, Renier G, et al. (2004) Mechanisms of azole resistance in petite mutants of Candida glabrata. Antimicrob Agents Chemother 48: 1788-1796.
10. Helmerhorst EJ, Venuleo C, Sanglard D, Oppenheim FG (2006) Roles of cellular respiration, CgCDR1, and CgCDR2 in Candida glabrata resistance to histatin 5. Antimicrob Agents Chemother 50: 1100-1103.
11. Sanglard D, Odds FC (2002) Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2: 73-85.
12. Tsai HF, Krol AA, Sarti KE, Bennett JE (2006) Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants. Antimicrob Agents Chemother 50: 1384-1392.
13. White TC, Holleman S, Dy F, Mirels LF, Stevens DA (2002) Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 46: 1704-1713.
14. Cowen LE, Anderson JB, Kohn LM (2002) Evolution of drug resistance in Candida albicans. Annu Rev Microbiol 56: 139-165.
15. Cowen LE, Steinbach WJ (2008) Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell 7: 747-764.
16. Lupetti A, Danesi R, Campa M, Del Tacca M, Kelly S (2002) Molecular basis of resistance to azole antifungals. Trends Mol Med 8: 76-81.
17. Marichal P, Koymans L, Willemsens S, Bellens D, Verhasselt P, et al. (1999) Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 145: 2701-2713.
18. Sanglard D, Ischer F, Calabrese D, Micheli M, Bille J (1998) Multiple resistance mechanisms to azole antifungals in yeast clinical isolates. Drug Resist Updat 1: 255-265.
19. Selmecki A, Forche A, Berman J (2006) Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 313: 367-370.
20. Selmecki A, Gerami-Nejad M, Paulson C, Forche A, Berman J (2008) An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. Mol Microbiol 68: 624-641.
21. Cowen LE, Lindquist S (2005) Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309: 2185-2189.
22. Cowen LE, Carpenter AE, Matangkasombut O, Fink GR, Lindquist S (2006) Genetic architecture of Hsp90-dependent drug resistance. Eukaryot Cell 5: 2184-2188.
23. Armengou A, Porcar C, Mascaro J, Garcia-Bragado F (1996) Possible development of resistance to fluconazole during suppressive therapy for AIDS associated cryptococcal meningitis. Clin Infect Dis 23: 1337-1338.
24. Berg J, Clancy CJ, Nguyen MH (1998) The hidden danger of primary fluconazole prophylaxis for patients with AIDS. Clin Infect Dis 26: 186-187.
25. Birley HD, Johnson EM, McDonald P, Parry C, Carey PB, et al. (1995) Azole drug resistance as a cause of clinical relapse in AIDS patients with cryptococcal meningitis. Int J STD AIDS 6: 353-355.
26. Paugam A, Dupouy-Camet J, Blanche P, Gangneux JP, Tourte-Schaefer C, et al. (1994) Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clin Infect Dis 19: 975-976.
27. Venkateswarlu K, Taylor M, Manning NJ, Rinaldi MG, Kelly SL (1997) Fluconazole tolerance in clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 41: 748-751.
28. Mondon P, Petter R, Amalfitano G, Luzzati R, Concia E, et al. (1999) Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans. Antimicrob Agents Chemother 43: 1856-1861.
29. Sionov E, Chang YC, Garraffo HM, Kwon-Chung KJ (2009) Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence. Antimicrob Agents Chemother 53: 2804-2815.
30. Posteraro B, Sanguinetti M, Sanglard D, La Sorda M, Boccia S, et al. (2003) Identification and characterization of a Cryptococcus neoformans ATP binding cassette (ABC) transporter-encoding gene, CnAFR1, involved in the resistance to fluconazole. Mol Microbiol 47: 357-371.
31. Polakova S, Blume C, Zarate JA, Mentel M, Jorck-Ramberg D, et al. (2009) Formation of new chromosomes as a virulence mechanism in yeast Candida glabrata. Proc Natl Acad Sci U S A 106: 2688-2693.
32. Rustchenko E, Sherman F (2002) Genetic instability of Candida albicans. In: Howard DH, ed. Fungi Pathogenic for Humans and Animals. New York: Marcel Dekker, Inc. pp 723-776.
33. Hartwell LH, Dutcher SK, Wood JS, Garvik B (1982) The fidelity of mitotic chromosome reproduction in S. cerevisiae. Rec Adv Yeast Mol Biol 1: 28-38.
34. Rosenstraus MJ, Chasin LA (1978) Separation of linked markers in Chinese hamster cell hybrids: mitotic recombination is not involved. Genetics 90: 735-760.
35. Torres EM, Sokolsky T, Tucker CM, Chan LY, Boselli M, et al. (2007) Effects of aneuploidy on cellular physiology and cell division in haploid yeast. Science 317: 916-924.
36. Zolan ME (1995) Chromosome-length polymorphism in fungi. Microbiol Rev 59: 686-698.
37. Varma A, Kwon-Chung KJ (1994) Formation of a minichromosome in Cryptococcus neoformans as a result of electroporative transformation. Curr Genet 26: 54-61.
38. Kaern M, Elston TC, Blake WJ, Collins JJ (2005) Stochasticity in gene expression: from theories to phenotypes. Nat Rev Genet 6: 451-464.
39. Stern C (1958) The nucleus and somatic cell variation. J Cell Physiol Suppl 52: 1-27; discussion 27-34.
40. Kafer E (1976) Mitotic crossing over and nondisjunction in translocation heterozygotes of Aspergillus. Genetics 82: 605-627.
41. Fernandez C, Lobo Md Mdel V, Gomez-Coronado D, Lasuncion MA (2004) Cholesterol is essential for mitosis progression and its deficiency inducespolyploid cell formation. Exp Cell Res 300: 109-120.
42. Yamaguchi M, Biswas SK, Ohkusu M, Takeo K (2009) Dynamics of the spindle pole body of the pathogenic yeast Cryptococcus neoformans examined by freezesubstitution electron microscopy. FEMS Microbiol Lett 296: 257-265.
43. Ganem NJ, Godinho SA, Pellman D (2009) A mechanism linking extra centrosomes to chromosomal instability. Nature 460: 278-282.
44. Wapinski I, Pfeffer A, Friedman N, Regev A (2007) Natural history and evolutionary principles of gene duplication in fungi. Nature 449: 54-61.
45. Rancati G, Pavelka N, Fleharty B, Noll A, Trimble R, et al. (2008) Aneuploidy underlies rapid adaptive evolution of yeast cells deprived of a conserved cytokinesis motor. Cell 135: 879-893.
46. Torelli R, Posteraro B, Ferrari S, La Sorda M, Fadda G, et al. (2008) The ATPbinding cassette transporter-encoding gene CgSNQ2 is contributing to the CgPDR1-dependent azole resistance of Candida glabrata. Mol Microbiol 68: 186-201.
47. Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G (2006) Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 43: 1069-1073.
48. Friese G, Discher T, Fussle R, Schmalreck A, Lohmeyer J (2001) Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease. AIDS 15: 2344-2345.
49. Yamazumi T, Pfaller MA, Messer SA, Houston AK, Boyken L, et al. (2003) Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans. J Clin Microbiol 41: 267-272.
50. Coste A, Selmecki A, Forche A, Diogo D, Bougnoux ME, et al. (2007) Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot Cell 6: 1889-1904.
51. Lee H, Bien CM, Hughes AL, Espenshade PJ, Kwon-Chung KJ, et al. (2007) Cobalt chloride, a hypoxia-mimicking agent, targets sterol synthesis in the pathogenic fungus Cryptococcus neoformans. Mol Microbiol 65: 1018-1033.
52. Chang YC, Kwon-Chung KJ (1994) Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol 14: 4912-4919.
53. Kavanaugh LA, Fraser JA, Dietrich FS (2006) Recent evolution of the human pathogen Cryptococcus neoformans by intervarietal transfer of a 14-gene fragment. Mol Biol Evol 23: 1879-1890.